Rebiotix starts enrolment in Phase III trial of RBX2660 for C. diff infection
US-based clinical-stage microbiome firm Rebiotix has started patient enrolment in a Phase III clinical trial of RBX2660 to prevent recurrent Clostridium difficile (C. diff) infection. (Source: Drug Development Technology)
Source: Drug Development Technology - August 8, 2017 Category: Pharmaceuticals Source Type: news

MyoKardia ’s Phase II trial for oHCM drug meets endpoints
MyoKardia has reported positive top-line results from the first cohort of its Phase II PIONEER-HCM clinical trial of mavacamten in patients with symptomatic, obstructive hypertrophic cardiomyopathy (oHCM). (Source: Drug Development Technology)
Source: Drug Development Technology - August 7, 2017 Category: Pharmaceuticals Source Type: news

Calithera begins Phase II trial of CB-839 to treat renal cell carcinoma
Pharmaceutical firm Calithera Biosciences has begun a Phase II clinical trial of CB-839 in combination with Afinitor (everolimus) ‎ for the treatment of patients with renal cell carcinoma (RCC). (Source: Drug Development Technology)
Source: Drug Development Technology - August 7, 2017 Category: Pharmaceuticals Source Type: news

UCL research indicates use of diabetes drug in Parkinson ’s disease
University College London (UCL) has carried out a study that indicated the potential of a common diabetes drug called exenatide as a disease-modifying therapy for treating Parkinson ’s disease. (Source: Drug Development Technology)
Source: Drug Development Technology - August 7, 2017 Category: Pharmaceuticals Source Type: news

Ritter ’s RP-G28 mitigates lactose intolerance symptoms in Phase IIb/III trial
US-based Ritter Pharmaceuticals has reported positive additional results from a Phase IIb/III trial of its product candidate RP-G28 in patients suffering from lactose intolerance (LI). (Source: Drug Development Technology)
Source: Drug Development Technology - August 6, 2017 Category: Pharmaceuticals Source Type: news

July ’s top stories: NCI and COG’s paediatric precision cancer trial, AstraZeneca’s NSCLC trial results
NIH ’s unit NCI and the COG initiated patient enrolment in a paediatric Phase II clinical trial to evaluate targeted cancer medicines, and AstraZeneca reported positive results from the FLAURA trial of Tagrisso to treat patients with locally advanced … (Source: Drug Development Technology)
Source: Drug Development Technology - August 6, 2017 Category: Pharmaceuticals Source Type: news

Eli Lilly ’s lasmiditan meets Phase III trial endpoints for migraine
Eli Lilly and Company has reported positive results from the Phase III SPARTAN clinical trial of lasmiditan for the acute treatment of migraines. (Source: Drug Development Technology)
Source: Drug Development Technology - August 6, 2017 Category: Pharmaceuticals Source Type: news

Foamix commences dosing in Phase III trial for acne drug
Foamix Pharmaceuticals has commenced patient dosing in a Phase III clinical trial (FX2017-22) of its product candidate FMX101 in patients with moderate-to-severe acne. (Source: Drug Development Technology)
Source: Drug Development Technology - August 6, 2017 Category: Pharmaceuticals Source Type: news

VM BioPharma begins dosing in Phase III trial of VM202 for NHU and PAD
Korean biopharmaceutical company ViroMed ’s US division VM BioPharma has begun dosing patients with VM202 in a Phase III clinical trial to treat non-healing diabetic foot ulcers (NHU) and associated peripheral artery disease (PAD). (Source: Drug Development Technology)
Source: Drug Development Technology - August 3, 2017 Category: Pharmaceuticals Source Type: news

FDA accepts Bellerophon ’s Phase IIb design for INOpulse in PH-ILD
The US Food and Drug Administration (FDA) has accepted Bellerophon Therapeutics ’ study design for the Phase IIb clinical trial of INOpulse in patients with Interstitial Lung Disease (ILD) associated pulmonary hypertension (PH). (Source: Drug Development Technology)
Source: Drug Development Technology - August 3, 2017 Category: Pharmaceuticals Source Type: news

First patient receives BCX7353 dosing in BioCryst ’s Phase II trial for HAE
US-based BioCryst Pharmaceuticals has started dosing patients in the Phase II ZENITH-1 exploratory clinical trial of BCX7353 to treat patients with hereditary angioedema (HAE). (Source: Drug Development Technology)
Source: Drug Development Technology - August 3, 2017 Category: Pharmaceuticals Source Type: news

M & As this week: Woden Venture Capital, Evotec
Woden Venture Capital (Woden) plans to acquire biotechnology company ACCUM Therapeutics for C$4.5m ($3.6m). (Source: Drug Development Technology)
Source: Drug Development Technology - August 3, 2017 Category: Pharmaceuticals Source Type: news

Deals this week: Milestone Pharmaceuticals, Homology Medicines, Ultragenyx Pharmaceutical
Canadian cardiovascular drug development company Milestone Pharmaceuticals has secured $55m through a series C funding round led by Novo Holdings. (Source: Drug Development Technology)
Source: Drug Development Technology - August 3, 2017 Category: Pharmaceuticals Source Type: news

DBV Technologies enrols first patient in Phase III peanut allergy trial
French biopharmaceutical firm DBV Technologies has started patient enrolment in a Phase III EPITOPE clinical trial of Viaskin Peanut to treat peanut allergy in young children. (Source: Drug Development Technology)
Source: Drug Development Technology - August 2, 2017 Category: Pharmaceuticals Source Type: news

Flex Pharma begins Phase II trial of FLX-787 for ALS in US
Flex Pharma has begun a Phase II clinical trial (COMMEND) of FLX-787 in the US to treat patients suffering from motor neuron disease (MND) with a focus on amyotrophic lateral sclerosis (ALS). (Source: Drug Development Technology)
Source: Drug Development Technology - August 2, 2017 Category: Pharmaceuticals Source Type: news